21180 Federal Register / Vol. 66, No. 82 / Friday, April 27, 2001 / Notices

• Coachella Branch Library, 1538 7th

Street, Coachella, California; telephone:

(760) 398–5148

• Brawley Public Library, 400 Main

Street, Brawley, California; telephone:

(760) 344–1891

• El Centro Public Library, 539 W.

State Street, El Centro, California;

telephone: (760) 337–4565

• Imperial Public Library, 200 W. 9th

Street, Imperial, California; telephone:

(760) 355–1332

• Indio Branch Library, 200 Civic

Center Mall, Indio, California;

telephone: (760) 347–2383

• Palm Springs Library, 300 S.

Sunrise Way, Palm Springs, California;

telephone: (760) 322–7323

• San Diego Central Library, 820 E

Street, San Diego, California; telephone:

(619) 236–5800

• Los Angeles Public Library, 630 W.

Fifth Street, Los Angeles, California

90071; telephone: (213) 228–7000

Dated: April 4, 2001.

LeGrand Neilson,

Deputy Regional Director.

[FR Doc. 01–10455 Filed 4–26–01; 8:45 am]

BILLING CODE 4310–MN–P

INTERNATIONAL TRADE

COMMISSION

[Investigation 332–430]

U.S.-Chile Free Trade Agreement:

Advice Concerning the Probable

Economic Effect

AGENCY: United States International

Trade Commission.

ACTION: Institution of investigation and

scheduling of public hearing.

EFFECTIVE DATE: April 23, 2001.

SUMMARY: Following receipt of a request

on April 17, 2001, from the United

States Trade Representative (USTR), the

Commission instituted investigation No.

332–430, U.S.-Chile Free Trade

Agreement: Advice Concerning the

Probable Economic Effect, under section

332(g) of the Tariff Act of 1930 (19

U.S.C. 1332(g)).

FOR FURTHER INFORMATION CONTACT:

Industry-specific information may be

obtained from James Lukes, Project

Leader (202–205–3426 or

lukes@usitc.gov) or David Lundy, Chief

of Industrial Minerals and Nonferrous

Metals (202–205–3439 or

lundy@usitc.gov), Office of Industries,

U.S. International Trade Commission,

Washington, DC 20436. For information

on the legal aspects of this investigation,

contact William Gearhart of the Office of

the General Counsel (202–205–3091 or

gearhart@usitc.gov). Hearing impaired

individuals are advised that information

on this matter can be obtained by

contacting the TDD terminal on (202)

205–1810. General information

concerning the Commission may also be

obtained by accessing its Internet server

(http://www.usitc.gov). The public

record for this investigation may be

viewed on the Commission’s electronic

docket (EDIS–ON–LINE) at http://

dockets/.usitc.gov/eol/public.

BACKGROUND: As requested by USTR,

the Commission will include the

following in its report—

1. Advice (to the President) with

respect to each item in chapters 1

through 97 of the Harmonized Tariff

Schedule of the United States (HTS), as

to the probable economic effect of

providing duty-free treatment for

imports of products of Chile on

industries in the United States

producing like or directly competitive

articles and on consumers;

2. Advice (to the President) with

respect to each product sector, of the

probable economic effect on U.S.

exports to Chile of the removal of

Chilean import duties; and

3. A review of U.S. service

transactions with Chile that (1) provides

an overview of the nature and extent of

such transactions; (2) highlights key

U.S. service industries that export

services to Chile or provide services

through U.S.-owned affiliates; (3)

identifies principal nontariff barriers

that impede U.S. participation in these

industries in the Chilean market; and (4)

assesses the effects of such barriers on

U.S. service providers.

As requested by the USTR, in

preparing its advice with respect to the

removal of U.S. duties on imports from

Chile, the Commission will assume that

any known U.S. nontariff barrier will

not be applicable to such imports; and

the Commission will note in its report

any instance in which the continued

application of a U.S. nontariff barrier

would result in different advice with

respect to the effect of the removal of

the duty. Similarly, in preparing its

advice with respect to the removal of

Chilean duties on U.S. products, the

Commission will assume that any

known Chilean nontariff barriers will

not be applicable to U.S. products; and

will note any instance where the

continued application of such a Chilean

nontariff barrier would result in

different advice.

The USTR requested the Commission

to provide the advice in a confidential

report by October 17, 2001. In his letter

to the Commission, the USTR stated that

the United States and Chile are engaged

in negotiations to reach a

comprehensive bilateral free trade

agreement. The USTR stated that further

advice from the Commission is needed

to assist in the process of achieving an

agreement.

PUBLIC HEARING: A public hearing in

connection with the investigation will

be held at the U.S. International Trade

Commission Building, 500 E Street SW.,

Washington, DC, beginning at 9:30 a.m.

on May 30, 2001. All persons shall have

the right to appear, by counsel or in

person, to present information and to be

heard. Requests to appear at the public

hearing should be filed with the

Secretary, United States International

Trade Commission, 500 E Street SW.,

Washington, DC 20436, no later than

5:15 p.m., May 22, 2001. Any

prehearing briefs (original and 14

copies) should be filed not later than

5:15 p.m., May 24, 2001; the deadline

for filing post-hearing briefs or

statements is 5:15 p.m., June 13, 2001.

To allow sufficient time for full

consideration, the Commission

encourages persons who appear at the

public hearing to submit any prepared

statements and accompanying material

to the Secretary by 5:15 p.m., May 24,

2001. In the event that, as of the close

of business on May 22, 2001, no

witnesses are scheduled to appear at the

hearing, the hearing will be canceled.

Any person interested in attending the

hearing as an observer or nonparticipant may call the Secretary to the

Commission (202–205–1806) after May

22, 2001, to determine whether the

hearing will be held.

WRITTEN SUBMISSIONS: In lieu of or in

addition to participating in the hearing,

interested parties are invited to submit

written statements (original and 14

copies) concerning the matters to be

addressed by the Commission in its

report on this investigation. Commercial

or financial information that a person

desires the Commission to treat as

confidential must be submitted in

accordance with section 201.6 of the

Commission’s rules of practice and

procedure (19 CFR 201.6). The

Commission’s Rules do not authorize

filing of submissions with the Secretary

by facsimile or electronic means. All

written submissions, except for

confidential business information, will

be made available in the Office of the

Secretary of the Commission for

inspection by interested parties. To be

assured of consideration by the

Commission, written statements relating

to the Commission’s report should be

submitted to the Commission at the

earliest practical date and should be

received no later than the close of

Federal Register / Vol. 66, No. 82 / Friday, April 27, 2001 / Notices 21181

business on June 13, 2001. All

submissions should be addressed to the

Secretary, United States International

Trade Commission, 500 E Street SW.,

Washington, DC 20436.

Persons with mobility impairments

who will need special assistance in

gaining access to the Commission

should contact the Office of the

Secretary at 202–205–2000.

LIST OF SUBJECTS: Chile, tariffs, and

imports.

By order of the Commission.

Issued: April 24, 2001.

Donna R. Koehnke,

Secretary.

[FR Doc. 01–10527 Filed 4–26–01; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA–191N]

Dispensing and Purchasing Controlled

Substances over the Internet

AGENCY: Drug Enforcement

Administration (DEA), Justice.

ACTION: Guidance.

SUMMARY: This notice is intended to

provide guidance to prescribers,

pharmacists, law enforcement

authorities, regulatory authorities, and

the public concerning the application of

current laws and regulations as they

relate to the use of the Internet for

dispensing, purchasing, or importing

controlled substances. This guidance

document explains when controlled

substances can be legally purchased

from U.S.-based Internet sites. This

notice clarifies that consumers must

have valid prescriptions to obtain

controlled substances legally and that

consumers cannot legally purchase

controlled substances from foreign

supplier Internet sites and have them

shipped to the U.S, unless the

consumers are registered with DEA as

controlled substances importers and are

in compliance with all DEA

requirements.

FOR FURTHER INFORMATION CONTACT:

Patricia M. Good, Chief, Liaison and

Policy Section, Office of Diversion

Control, Drug Enforcement

Administration, Washington, DC 20537.

Telephone (202) 307–7297.

SUPPLEMENTARY INFORMATION:

Why is This Notice Necessary?

With the advent of Internet

pharmacies, DEA registrants and the

public have asked how these Internet

pharmacies fit into the requirements

that currently exist for the prescribing

and dispensing of controlled substances.

DEA is issuing this notice to provide

guidance to prescribers, pharmacists,

law enforcement authorities, regulatory

authorities, and the public about the

application of current laws and

regulations to the use of the Internet for

prescribing, dispensing, purchasing, or

importing controlled substances.

This document is in the format of

questions and answers. The first section

provides the context for this notice. The

next two sections address issues that

apply to DEA registrants and

consumers.

General Questions

What are Controlled Substances?

Most drugs that require a prescription

from a doctor are not controlled

substances. The Controlled Substances

Act and its implementing regulations,

however, assign certain substances to

one of five ‘‘schedules.’’ These

substances are placed in a schedule

based on their potential for abuse,

which may lead to physical or

psychological dependency. Schedule I

substances have no accepted medical

use for treatment in the United States

and are not available by prescription.

Schedule II through V substances have

accepted medical use and varying

potentials for abuse and dependency.

Practitioners (e.g., doctors, dentists,

veterinarians, physician assistants,

advance practice nurses) who are

licensed by a State and registered with

DEA may prescribe these substances.

Controlled substances include narcotics

(pain relievers), stimulants, depressants,

hallucinogens, and anabolic steroids. A

complete list of controlled substances

can be found in Title 21 of the Code of

Federal Regulations (CFR) part 1308.

Examples of controlled substances are

shown below.

Schedule Example of controlled substances

Schedule I ............................ Heroin, marijuana, mescaline, methcathinone,

Schedule II ........................... Amphetamine, codeine, fentanyl, Hydromorphone, meperidine, methadone, Methylphenidate (Ritalin), morphine,

oxycodone, pentobarbital, phencyclidine (PCP), secobarbital

Schedule III .......................... Anabolic steroids, phendimetrazine, and products that contain small quantities of certain schedule II controlled

substances, such as codeine, in combination with noncontrolled ingredients, such as aspirin.

Schedule IV .......................... Alprazolam (Xanax), chlordiazepoxide (Librium), diazepam (Valium), lorazepam (Ativan), phenobarbital,

phentermine

Schedule V ........................... Buprenorphine and many cough Preparations that contain a limited amount of codeine

What are the Basic Requirements for

Prescribing, Dispensing, and Importing

Controlled Substances?

Only practitioners acting in the usual

course of their professional practice may

prescribe controlled substances. These

practitioners must be registered with

DEA and licensed to prescribe

controlled substances by the State(s) in

which they operate. Pharmacies filling

prescriptions for controlled substances

must also be registered with DEA and

licensed to dispense controlled

substances by the State(s) in which they

operate. A prescription not issued in the

usual course of professional practice or

not for legitimate and authorized

research is not considered valid. Both

the practitioner and the pharmacy have

a responsibility to ensure that only

legitimate prescriptions are written and

filled.

Pharmacists must receive written and

manually signed prescriptions for

Schedule II substances. They may

receive oral or faxed prescriptions for

Schedules III–V substances provided

they confirm the legitimacy of the

prescription and the practitioner.

Prescriptions for Schedule II substances

may not be refilled. Prescriptions for

Schedules III–V controlled substances

may be refilled five times, but no

prescription may be filled or refilled

more than six months after the date on

which the prescription was issued. Only

those people who are registered with

DEA as importers and who are in

compliance with DEA requirements may

have controlled substances shipped into

the customs territory or jurisdiction of

the U.S. from a foreign country.

DEA regulations covering

prescriptions can be found in Title 21 of

the Code of Federal Regulations, part

1306; rules on importation are found in

21 CFR 1312.